Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Calliditas Therapeutics AB - ADR before investing.

In this article, we go over a few key elements for understanding Calliditas Therapeutics AB - ADR’s stock price such as:

• Calliditas Therapeutics AB - ADR’s current stock price and volume
• Why Calliditas Therapeutics AB - ADR’s stock price changed recently
• Upgrades and downgrades for CALT from analysts
• CALT’s stock price momentum as measured by its relative strength

About Calliditas Therapeutics AB - ADR (CALT)

Before we jump into Calliditas Therapeutics AB - ADR’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Want to learn more about Calliditas Therapeutics AB - ADR’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Calliditas Therapeutics AB - ADR.

Calliditas Therapeutics AB - ADR’s Stock Price as of Market Close

As of April 11, 2024, 4:00 PM, CST, Calliditas Therapeutics AB - ADR’s stock price was $20.53.

Calliditas Therapeutics AB - ADR is down 4.6% from its previous closing price of $21.52.

During the last market session, Calliditas Therapeutics AB - ADR’s stock traded between $20.64 and $21.91. Currently, there are 26.84 million shares of Calliditas Therapeutics AB - ADR stock available for purchase.

Unfortunately, Calliditas Therapeutics AB - ADR’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Calliditas Therapeutics AB - ADR Stock Price History

Calliditas Therapeutics AB - ADR’s (CALT) price is currently down 2.28% so far this month.

During the month of April, Calliditas Therapeutics AB - ADR’s stock price has reached a high of $23.00 and a low of $0.00.

Over the last year, Calliditas Therapeutics AB - ADR has hit prices as high as $29.30 and as low as $15.25. Year to date, Calliditas Therapeutics AB - ADR’s stock is up 20.76%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Calliditas Therapeutics AB - ADR Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 10, 2024,, no analysts have changed their rating of Calliditas Therapeutics AB - ADR’s stock over the last month.

Additionally, you'll want to evaluate Calliditas Therapeutics AB - ADR’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Calliditas Therapeutics AB - ADR’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Calliditas Therapeutics AB - ADR’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Calliditas Therapeutics AB - ADR (CALT) by visiting AAII Stock Evaluator.

Relative Price Strength of Calliditas Therapeutics AB - ADR

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 10, 2024, Calliditas Therapeutics AB - ADR has a weighted four-quarter relative price strength of -7.57%, which translates to a Momentum Score of 42 and is considered to be Average.

Want to learn more about how Calliditas Therapeutics AB - ADR is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Calliditas Therapeutics AB - ADR Stock Price: Bottom Line

As of April 11, 2024, Calliditas Therapeutics AB - ADR’s stock price is $20.53, which is down 4.6% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Calliditas Therapeutics AB - ADR stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.